Biotech

All Articles

Lykos will definitely talk to FDA to reconsider its own decision following rejection of MDMA treatment for post-traumatic stress disorder

.Following an unsatisfactory presenting for Lykos Therapeutics' MDMA applicant for trauma at a lates...

AN 2 one-halfs roll call, stops phase 3 trial after records dissatisfy

.AN2 Rehabs is reassessing its service in response to lackluster midphase records, promising to lay ...

Merck spends $700M for bispecific, spying autoimmune opening and possibility to test Amgen in cancer cells

.Merck &amp Co. is actually spending $700 million ahead of time to test Amgen in a blood cancer mark...

Gilead pays J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences on the verge of an FDA decision for its liver illness medicine seladelpa...

' All hands on deck' at Lilly as peers target weight problems market

.Chief executive officer David Ricks may view the firms establishing camping tents at basecamp respo...

Entero giving up team, moving out of workplace and also stopping briefly R&ampD

.Bed Liquidators has switched Entero Rehabs white as a slab. The creditor purchased Entero to repay ...

Exelixis goes down ADC after determining it's no match for Tivdak

.Exelixis is actually losing hope on its tissue aspect (TF)- targeting antibody-drug conjugate after...

Relay dislikes SHP2 inhibitor after Genentech leaves behind

.Three weeks after Roche's Genentech device walked away from an SHP2 inhibitor pact, Relay Rehab has...

Stoke's Dravet disorder med discharged of predisposed professional hold

.Stoke Therapeutics' Dravet disorder medicine has actually been freed from a predisposed hold, clear...

Fierce Biotech's Gabrielle Masson shows Tough 15 at NYSE

.Tough Biotech Associate Publisher Gabrielle Masson provided the 2024 course of Brutal 15 winners on...